Clinical Trials

A Phase II Study of Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Endometrial Cancer Lymphadenectomy Trial (ECLAT)

Cytoreductive Surgery in Advanced Endometrial Cancer. Multicenter Retrospective Study

Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Dactinomycin or Methotrexate in Treating Patients with Low Risk Gestational Trophoblastic Neoplasia

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

A Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer(SUNNY)

A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery

A Phase II, Open-Label, Randomized, Multi-Centre Study of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer

A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer 

Platine, Avastin and Olaparib in 1st line Ovarian Cancer

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery

A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

First line weekly carboplatin and paclitaxel versus every 3 weeks carboplatin/paclitaxel in patients with ovarian cancer: phase III multicentre trial 

Randomized phase III  trial on  Trabectedin (ET 743) vs clinician’s choice chemotherapy   in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or  BRCAness phenotype patients 

Pathway to diagnosis of ovarian cancer: an observational retrospective multicentred study